EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Heterologous Expression and Optimization of Fermentation Conditions for Recombinant Ikarugamycin Production

Julia K Evers, Anna Glöckle, Monique Wiegand, Sebastian Schuler, Manuel Einsiedler, Tobias A M Gulder

Biotechnology and Bioengineering · 2025-04 · 122 (4) · 974-982

DOI: 10.1002/bit.28919 ↗

At a glance

Journal article in Biotechnology and Bioengineering, published online on 2025-01-11. Written by Julia K Evers and 5 co-authors. Institution: Chair of Technical Biochemistry, Technische Universität Dresden, Dresden, Saxony, Germany. Major MEDLINE topics: Recombinant Proteins, Escherichia coli, Lactams, Macrocyclic, Lactams. Cited 8 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY 4.0). Funded by: The study was supported by the Deutsche Forschungsgemeinschaft (DFG; GU 1233/2-1, GU 1233/2-2, and INST 269/973-1)., Deutsche Forschungsgemeinschaft.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Ikarugamycin is a member of the natural product family of the polycyclic tetramate macrolactams (PoTeMs). The compound exhibits a diverse range of biological activities, including antimicrobial, antiprotozoal, anti‐leukemic, and anti‐inflammatory properties. In addition, it interferes with several crucial cellular functions, such as oxidized low‐density lipoprotein uptake in macrophages, Nef‐induced CD4 cell surface downregulation, and mechanisms of endocytosis. It is, therefore, used as a tool compound to study diverse biological processes. However, ikarugamycin commercial prices are very high, with up to 1300 € per 1 mg, thus limiting its application. We, therefore, set out to develop a high‐yielding recombinant production platform of ikarugamycin by screening different expression vectors, recombinant host strains, and cultivation conditions. Overall, this has led to overproduction levels of more than 100 mg/L, which, together with a straightforward purification protocol, establishes biotechnological access to affordable ikarugamycin enabling its increased use in biomedical research in the future.

Subjects

MeSH terms (MEDLINE)

Recombinant ProteinsEscherichia coliLactams, MacrocyclicLactamsFermentation

Author keywords

fermentationheterologous expressionikarugamycinoptimized production

Substances

Recombinant ProteinsLactams, MacrocyclicLactams

Authors and institutions

  • Chair of Technical Biochemistry, Technische Universität Dresden, Dresden, Saxony, Germany.
  • Department of Natural Product Biotechnology, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Department of Pharmacy at Saarland University, PharmaScienceHub (PSH), Helmholtz Centre for Infection Researc…

Funding

  • The study was supported by the Deutsche Forschungsgemeinschaft (DFG; GU 1233/2-1, GU 1233/2-2, and INST 269/973-1).
  • Deutsche Forschungsgemeinschaft

Cite

APA

Evers, J. K., Glöckle, A., Wiegand, M., Schuler, S., Einsiedler, M., & Gulder, T. A. M. (2025). Heterologous Expression and Optimization of Fermentation Conditions for Recombinant Ikarugamycin Production. Biotechnology and Bioengineering, 122(4), 974-982. https://doi.org/10.1002/bit.28919

Vancouver

Evers JK, Glöckle A, Wiegand M, Schuler S, Einsiedler M, Gulder TAM. Heterologous Expression and Optimization of Fermentation Conditions for Recombinant Ikarugamycin Production. Biotechnology and Bioengineering. 2025;122(4):974-982. doi:10.1002/bit.28919

BibTeX
@article{Evers2025,
  author = {Evers, Julia K and Glöckle, Anna and Wiegand, Monique and Schuler, Sebastian and Einsiedler, Manuel and Gulder, Tobias A M},
  title = {Heterologous Expression and Optimization of Fermentation Conditions for Recombinant Ikarugamycin Production},
  journal = {Biotechnology and Bioengineering},
  year = {2025},
  volume = {122},
  number = {4},
  pages = {974--982},
  doi = {10.1002/bit.28919}
}
Start for free →